Drug Trial Radar · NCT06293651
Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
125
Planned (sponsor's estimate)
Start
Apr 18, 2024
Primary completion
Jan 2026
Study completion Oct 2029
Sponsor
- Lead sponsor
- Dong-A ST Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an Open-Label, Phase 1/2a, First-in-Human, Dose-Escalation, Dose-Expansion, and Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors.
Conditions
- Locally Advanced or Metastatic Solid Tumors
Interventions
DA-4505Drug
Phase 1a: Dose escalation Phase 1b: OBD and MTD Phase 2a: RP2D
DA-4505 + PembrolizumabDrug
Phase 1a/b: OBD, MTD of DA-4505 + 200mg of Pembrolizumab Phase 2a: RP2D of DA-4505 + 200mg of Pembrolizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of adverse events (AEs) meeting protocol-defined dose-limiting toxicity(DLT) criteriaTime frame: Cycle 1(21 days) in dose escalation
- PK parameters for DA-4505 (Peak Plasma Concentration (Cmax))Time frame: Day 1 and 2 of first 2 cycles (every 21 days)
- PK parameters for DA-4505 (Area Under the Curve (AUC))Time frame: Day 1 and 2 of first 2 cycles (every 21 days)
- PK parameters for DA-4505 (half-life (t1/2))Time frame: Day 1 and 2 of first 2 cycles (every 21 days)
- Response per revised "Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1)Time frame: approximately 12 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea · Recruiting
Severance Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.